Digital Therapeutics: Evidence-Based Digital Interventions for Disease Prevention, Treatment, and Personalized Healthcare
Abstract
Abstract Digital therapeutics (DTx) represent an emerging category of evidence-based healthcare interventions that use software to prevent, manage, or treat diseases and disorders. Unlike conventional wellness applications, DTx are designed around therapeutic objectives and are expected to demonstrate clinical benefits through scientific evaluation. They may incorporate cognitive behavioral therapy, behavioral modification, patient education, medication adherence support, physiological monitoring, personalized algorithms, and other software-mediated interventions. Digital therapeutics have been investigated across mental health, sleep disorders, substance-use disorders, diabetes, hypertension, neurological disorders, cardiovascular disease, and other chronic conditions. Clinical evidence indicates that appropriately designed DTx can improve selected clinical outcomes, although effectiveness varies according to disease, intervention design, patient population, adherence, and duration of treatment. Recent meta-analyses have reported beneficial effects of DTx on glycemic control and cardiovascular risk factors, while randomized trials have demonstrated clinically meaningful effects of digital cognitive behavioral therapy for insomnia. At the same time, important challenges remain concerning clinical validation, cybersecurity, privacy, interoperability, health inequities, reimbursement, regulatory classification, long-term adherence, and real-world effectiveness. A 2026 assessment of FDA-authorized DTx found substantial heterogeneity in the evidence supporting different products, emphasizing the need for transparent and timely evidence generation. This review discusses the definition, mechanisms, applications, clinical evidence, advantages, limitations, regulatory considerations, and future prospects of digital therapeutics. DTx are likely to become an important component of personalized and hybrid healthcare, provided that their development remains grounded in rigorous clinical evidence and responsible digital-health governance. Keywords: digital therapeutics, DTx, digital health, digital medicine, software therapeutics, digital healthcare, personalized medicine, mHealth, artificial intelligence, behavioral therapy, clinical trials, remote healthcare 1. Introduction The rapid development of smartphones, wearable devices, cloud computing, artificial intelligence (AI), connected medical devices, and health-information technologies has transformed the delivery of healthcare. Digital health technologies can now collect health information continuously, communicate with patients remotely, provide personalized interventions, and support clinical decision-making. Within this rapidly expanding field, digital therapeutics (DTx) have emerged as a distinct category of software-based healthcare intervention. DTx are generally designed to prevent, manage, or treat a medical disorder by delivering a therapeutic intervention through software. They can operate through smartphones, tablets, computers, wearable devices, connected sensors, or combinations of software and hardware. Importantly, a DTx is not simply a health-information application or wellness platform. Its therapeutic claims should be supported by appropriate scientific and clinical evidence (Yao et al., 2024; Murray et al., 2016). The increasing interest in DTx reflects several limitations of conventional healthcare. Many chronic diseases require continuous behavioral management rather than episodic treatment. Healthcare systems may also face shortages of trained professionals, geographical barriers, high treatment costs, and limited access to specialized services. Digital interventions potentially allow therapeutic support to be delivered at scale and at times convenient to patients. Clinical research has expanded rapidly. A survey of ClinicalTrials.gov identified 280 eligible DTx-related clinical trials as of August 2023, with approximately two-thirds of completed trials using randomized controlled designs. Mental and behavioral disorders, neurological disorders, and metabolic diseases were among the major research areas (Yao et al., 2024). Therefore, DTx may represent an important transition from conventional medicine toward continuous, personalized, data-driven healthcare. 2. Definition and Concept of Digital Therapeutics Digital therapeutics can be considered a specialized component of digital health. Their defining characteristic is the delivery of a therapeutic intervention through software. The International Organization for Standardization's work on personalized digital health and DTx and the broader DTx literature describe these technologies as software systems intended to generate and deliver a medical intervention for preventing, treating, or alleviating disease, disorder, condition, or injury (ISO, 2023). A DTx may include: Cognitive behavioral therapy Behavioral modification Digital patient education Medication-adherence interventions Disease self-management Lifestyle modification Sleep interventions Addiction-management programs Digital rehabilitation Personalized coaching Symptom monitoring Biofeedback Algorithm-driven interventions Sensor-supported therapeutic interventions AI-assisted personalization The therapeutic intervention may be completely automated or may operate in combination with healthcare professionals. A useful distinction can therefore be made: Digital health category Primary purpose Wellness application General health and fitness Electronic health record Storage and management of clinical information Telemedicine Remote communication with healthcare professionals Clinical decision support Assistance with clinical decisions Remote patient monitoring Collection of physiological/clinical data Digital therapeutic Software-delivered therapeutic intervention Digital medicine Broader category combining digital technologies with medical care Thus, all DTx are digital-health technologies, but not all digital-health technologies are DTx. 3. How Digital Therapeutics Work DTx can influence health through several mechanisms. 3.1 Behavioral modification Many chronic diseases are strongly influenced by behavior. DTx can provide reminders, goal-setting, feedback, educational content, and behavioral reinforcement. For example, an intervention for diabetes may encourage: Regular physical activity Dietary modification Blood-glucose monitoring Medication adherence Weight management Self-monitoring 3.2 Cognitive behavioral therapy Digital cognitive behavioral therapy (dCBT) is one of the best-developed applications of digital therapeutics. It has been extensively investigated for insomnia, anxiety, depression, and other behavioral conditions. A large randomized clinical trial involving 1,711 participants demonstrated beneficial effects of digital CBT for insomnia on sleep and broader measures of health and psychological well-being (Espie et al., 2019). 3.3 Continuous monitoring and feedback Wearables and connected medical devices can provide physiological data that allow digital interventions to respond dynamically to patient status. Potential inputs include: Heart rate Blood pressure Blood glucose Physical activity Sleep Respiratory parameters Body weight Medication adherence The resulting feedback loop can be represented conceptually as: Patient → Data collection → Algorithm → Personalized intervention → Behavioral/physiological response → New data This creates a continuous therapeutic cycle rather than an episodic healthcare encounter. 3.4 Artificial intelligence and personalization AI can potentially personalize DTx according to patient characteristics and response patterns. Machine-learning algorithms may identify behavioral patterns and modify intervention intensity, timing, or content. However, AI-based personalization introduces additional concerns regarding algorithmic bias, explainability, data quality, cybersecurity, and clinical validation. 4. Major Clinical Applications 4.1 Mental health Mental health represents one of the most important areas for DTx development. Applications include: Depression Anxiety Stress Insomnia Post-traumatic stress symptoms Substance-use disorders Behavioral disorders Digital interventions can provide structured psychological exercises without requiring every therapeutic interaction to occur face-to-face. However, DTx should not automatically be regarded as substitutes for professional mental-health care. Patients with severe symptoms, suicidal ideation, psychosis, or other high-risk conditions require appropriate clinical assessment and treatment. 4.2 Insomnia and sleep disorders Digital CBT for insomnia is among the strongest examples of evidence-based DTx. In a large randomized clinical trial, digital CBT improved insomnia-related outcomes and broader psychological and health-related measures compared with sleep-hygiene education (Espie et al., 2019). Subsequent analyses of randomized-trial data have also reported reductions in anxiety symptoms associated with digital CBT for insomnia, suggesting that improvement in sleep may influence broader psychological outcomes (Henry et al., 2023). 4.3 Diabetes management Diabetes is particularly suitable for digital therapeutics because effective management requires continuous self-management. Potential DTx functions include: Blood-glucose monitoring Dietary management Exercise recommendations Medication reminders Weight management Patient education Behavioral coaching Personalized feedback A 2025 systematic review and meta-analysis of 19 randomized trials involving 3,264 participants reported that DTx interventions were associated with reductions in HbA1c, fasting blood glucose, and BMI, although effects varied between diabetes subtypes and outcomes (Li et al., 2025). These findings suggest that DTx could become an important
